MCL1 and non-Hodgkin lymphoma: However, the single‐agent efficacy of venetoclax has not been as extensive and durable in patients with relapsed or refractory NHL [22], a collection of B‐cell malignancies where MCL‐1 is established as a factor driving resistance to venetoclax [17, 23, 24, 25].